Our object,ive was to compare the usefulness of tumor markers, serum CA125 and CA130 in differentiating malignant, fr om benign pelvic masses.

Serum CA125 and CA130 levels were measured by immunoradiometric assay in total 135 sarnples which were cnllected from 91 patients with benign peluic masses, 21 patients with ovarian cancer, 3 patients with no evidence of disease after treatrnent for ovarian cancer and 20 apparently healthy.

In epithelial ovarian cancer, mean value of serum CA125 and CA130 were 1224.0 U/ ml and 891.0 U/ml, respectively, Serum. CA125 and CA130 levels were above 35 U/ml in 90,5% and 81.0/ af patients with maligna.nt pelvic rnasses, respectively, Serum CA130 levels showed lower false positive rate in patients with benign pelvic masses, 34.1%(>35U/ml) than that nf serurn CA125 levels 51.6%(>35U/rnl). In control group, serum CA125 and CA130 Ievels were atxwe 65 U/ml in 13.0% and 0% respectively. Values of both markers correlated each others very well. Regression equation between CA125 and CA130 is following; CA130 = 10.0+0.673 CA125 and carrelation coefficient is 0.992, Combining of CA125 and CA130, a sensitivity was 81.0% (>35U/ml) and 81.0% (>65U/ml) similar to CA125 levels alone, 90.5% (>35U/ml) and 85.7% (>65U/ml). In specificity, combining of serum CA125 aad CA130, 68.1/. (>36U/ml), 76.9 /a ( > 65U/ml) were much higher than CA125 alone, 48.4% (>36U/ml), 71.4% (>66U/ml). And diagnostic accuracy was higher in the combined use of CA125 and CA130, 69.6% (>35U/ml), 77,7% (>65U/ml) than CA125 alone, 56.3% 35U/ml), 74.1% (>65U/ml).

Valuee of serum CA130 well correlated with thaee of CA125 and cornbined use of both markers can obtain an acceptable sensitivity and a better specificity than thous of aerum CA125 alone in ditfferentiatjng malignant from henign pelvic masses.